Ondansetron Dosage Guidelines for Teenagers
Weight-Based Dosing
- For teenagers weighing ≤15 kg, the recommended dosage of ondansetron is 30 mg twice daily, according to the Journal of Clinical Oncology 1
- For teenagers weighing >15-23 kg, the recommended dosage of ondansetron is 45 mg twice daily, as per the Journal of Clinical Oncology 1
- For teenagers weighing >23-40 kg, the recommended dosage of ondansetron is 60 mg twice daily, based on the Journal of Clinical Oncology guidelines 1
- For teenagers weighing >40 kg, the American College of Clinical Oncology recommends an adult dose of 8 mg twice daily 1
Administration Timing and Duration
- The American Society of Clinical Oncology recommends that for chemotherapy-induced nausea and vomiting, the first dose of ondansetron should be administered 30 minutes before the start of emetogenic chemotherapy, with subsequent doses 8 hours after the first dose, followed by twice daily dosing for 2 days after completion of chemotherapy 3
Formulation Options
- Oral dissolving tablets are a useful formulation option for teenagers who have difficulty swallowing pills, as recommended by the Journal of Clinical Oncology 1
- Oral soluble films are an alternative option that dissolves on the tongue, according to the Journal of Clinical Oncology 1
Safety Considerations
- No dosage adjustment is required based on age alone in teenagers, as stated by the American Academy of Pediatrics, in guidelines summarized by Praxis Medical Insights 2
- No dosage adjustment is required for teenagers with renal impairment, according to the American Academy of Pediatrics, in guidelines summarized by Praxis Medical Insights 2
Clinical Pearls
- For teenagers receiving highly emetogenic chemotherapy, the National Comprehensive Cancer Network recommends considering adding dexamethasone to improve antiemetic efficacy 3
- For breakthrough nausea/vomiting, additional doses of ondansetron may be required, but should not exceed the maximum daily recommended dose, as recommended by the National Comprehensive Cancer Network and the Journal of Clinical Oncology 3, 4